Status and prospects of in vitro tests in risk assessment

According to the new chemicals policy of the European Union (EU), most chemicals, i.e. the 20,000 chemicals manufactured or imported at 1-10 tons annually, should be tested primarily by using in vitro methods. Also, for other chemicals, the use of in vitro methods is encouraged in the testing strategies given in the draft EU legislation. However, the validation and international acceptance of in vitro tests has been slow. Only recently has the OECD approved four new in vitro test methods, validated by the European Centre for the Validation of Alternative Methods. An analysis of ten randomly selected risk assessment reports of the EU Existing Chemicals Risk Assessment Programme showed that in vitro studies, for example, on cytotoxicity to different cell cultures, cell transformation, metabolism and skin penetration (a total of 115 studies) were used for the assessments. Key metabolic pathways and mechanisms of toxicity have been elucidated, for some chemicals, by using in vitro methods. On the other hand, the results of in vitro studies were regarded as secondary or unreliable in some cases. For several toxic endpoints, in vitro methods will probably serve as screening tools and for mechanistic studies, while target organ toxicity or physiologically regulated adverse effects caused by long-term exposure are difficult to observe without the use of animal models.     

The importance of a validated standard methodology to define in vitro toxicity of nano-TiO2

Several in vitro studies on the potential toxicity of nano-TiO(2) have been published and recent reviews have summarised them. Most of these reports concluded that physicochemical properties of nanoparticles are fundamental to their toxicological effects. No published review has compared in vitro tests with similar test strategies in terms of exposure duration and measured endpoints and for this reason we have attempted to assess the degree of homogeneity among in vitro tests and to assess if they afford reliable data to support risk assessment. The responses in different in vitro tests appeared to be unrelated to primary particle size. The biologically effective concentrations in different tests can be seen to differ by as many as two orders of magnitude and such differences could be explained either by different sensitivities of cell lines to nanoparticles or by effect of the test media. Our review indicates that even when the in vitro tests measure the same biomarkers with the same exposure duration and known primary particle sizes, it is insufficient merely to use such data for risk assessment. In the future, validated standard methods should include a limited number of cell lines and an obligatory selection of biomarkers. For routine purposes, it is important that assays can be easily conducted, false negatives and false positives are excluded and unbiased interpretation of results is provided. Papers published to date provide an understanding of the mode on nano-TiO(2) action but are not suitable for assessment and management of risk.     

The new EU REACH regulation has finally been adopted: is this the end of the campaign trail... or just the beginning?

The final EU REACH legislation has recently been adopted. This article considers the progress that has been made toward reducing the numbers of animals likely to be required to fulfil the testing requirements, and also considers the benefits to animal welfare and science that have arisen since the original REACH system proposals were published in 2003. Several positive changes have been made, including: the use of exposure-based testing; the requirement for scientific justification of any proposed animal testing; mandatory data sharing; and the fact that the EU is to take responsibility for the development and validation of alternative methods. While these changes are to be commended, there is still much room for improvement, particularly with respect to the adoption of integrated testing strategies that make maximum use of non-animal approaches to expedite the risk assessment process of existing chemicals, with the use of refined and updated animal tests only as a last resort.     

Ecotoxicity testing: science, politics and ethics

Animal welfare organisations have long been concerned about the use of animals for ecotoxicity testing. Ecotoxicity testing is a necessary part of the statutory risk assessment of chemicals that may be released into the environment. It is sometimes also carried out during the development of new chemicals and in the investigation of pollution in the field. This review considers the existing requirements for ecotoxicity testing, with particular reference to practices in the European Union, including the recent REACH system proposals, before discussing criticisms that have been made of existing practices for environmental risk assessment. These criticisms have been made on scientific and ethical grounds, as well as on questions of cost. A case is made for greater investment in the development of alternative testing methods, which could improve the science, as well as serving the cause of animal welfare. It has frequently been suggested that the statutory requirements for environmental risk assessment are too rigid and bureaucratic. A case is made for flexibility and the greater involvement of scientists in the risk assessment procedure, in the interests of both improved science and improved animal welfare.     

FRAME and the Royal Commission on Environmental Pollution: common recommendations for assessing risks posed by chemicals under the EU REACH system

This document discusses recommendations made by FRAME and the Royal Commission on Environmental Pollution (RCEP) with regard to the current European Commission proposals on the Registration, Evaluation and Authorisation of Chemicals (REACH) system for assessing the risks of chemicals to humans, wildlife and the environment. Of several common aims and recommendations, the two most important are: a) the greater use of non-animal testing methods, especially computational prediction methods (for example, [quantitative] structure-activity relationships, expert systems and biokinetic modelling) for prioritising chemicals for hazard assessment; and b) the greater use of intelligent exposure-based targeted risk assessment, with less emphasis being placed on tonnage-triggers. FRAME has produced a decision-tree testing scheme to illustrate the way in which these approaches could be used, together with in vitro test methods. This scheme has been slightly modified to take account of proposals subsequently made by the RCEP. In addition, FRAME points out that new and improved computational methods are needed through more coordinated research, and that these and existing methods need to be validated. The similarities between the independent publications of FRAME and the RCEP add weight to the recommendations that each have made concerning the implementation of the REACH system.     

FRAME and the Royal Commission on Environmental Pollution: common recommendations for assessing risks posed by chemicals under the EU REACH system

This document discusses recommendations made by FRAME and the Royal Commission on Environmental Pollution (RCEP) with regard to the current European Commission proposals on the Registration, Evaluation and Authorisation of Chemicals (REACH) system for assessing the risks of chemicals to humans, wildlife and the environment. Of several common aims and recommendations, the two most important are: a) the greater use of non-animal testing methods, especially computational prediction methods (for example, [quantitative] structure-activity relationships, expert systems and biokinetic modelling) for prioritising chemicals for hazard assessment; and b) the greater use of intelligent exposure-based targeted risk assessment, with less emphasis being placed on tonnage-triggers. FRAME has produced a decision-tree testing scheme to illustrate the way in which these approaches could be used, together with in vitro test methods. This scheme has been slightly modified to take account of proposals subsequently made by the RCEP. In addition, FRAME points out that new and improved computational methods are needed through more coordinated research, and that these and existing methods need to be validated. The similarities between the independent publications of FRAME and the RCEP add weight to the recommendations that each have made concerning the implementation of the REACH system.     

Intelligent testing strategies for chemicals testing -- a case of more haste, less speed?

The prospects for using (Q)SAR modelling, read-across (chemical) and other non-animal approaches as part of integrated testing strategies for chemical risk assessment, within the framework of the EU REACH legislation, are considered. The potential advantages and limitations of (Q)SAR modelling and read-across methods for chemical regulatory risk assessment are reviewed. It is concluded that it would be premature to base a testing strategy on chemical-based computational modelling approaches, until such time as criteria to validate them for their reliability and relevance by using independent and transparent procedures, have been agreed. This is mainly because of inherent problems in validating and accepting (Q)SARs for regulatory use in ways that are analogous to those that have been developed and applied for in vitro tests. Until this issue has been resolved, it is recommended that testing strategies should be developed which comprise the integrated use of computational and read-across approaches. These should be applied in a cautious and judicious way, in association with available tissue culture methods, and in conjunction with metabolism and biokinetic studies. Such strategies should be intelligently applied by being driven by exposure information (based on bioavailability, not merely on production volume) and hazard information needs, in preference to a tick-box approach. In the meantime, there should be increased efforts to develop improved (Q)SARs, expert systems and new in vitro methods, and, in particular, ways to expedite their validation and acceptance must be found and prospectively agreed with all major stakeholders.     

Adopting Lead-Free Electronics: Policy Differences and Knowledge Gaps

For more than a decade, the use of lead (Pb) in electronics has been controversial: Indeed, its toxic effects are well documented, whereas relatively little is known about proposed alternative materials. As the quantity of electronic and electrical waste (e‐waste) increases, legislative initiatives and corporate marketing strategies are driving a reduction in the use of some toxic substances in electronics. This article argues that the primacy of legislation over engineering and economics may result in selecting undesirable replacement materials for Pb because of overlooked knowledge gaps. These gaps include the need for: assessments of the effects of changes in policy on the flow of e‐waste across state and national boundaries; further reliability testing of alternative solder alloys; further toxicology and environmental impact studies for high environmental loading of the alternative solders (and their metal components); improved risk assessment methodologies that can capture complexities such as changes in waste management practices, in electronic product design, and in rate of product obsolescence; carefully executed allocation methods when evaluating the impact of raw material extraction; and in‐depth risk assessment of alternative end‐of‐life (EOL) options. The resulting environmental and human health consequences may be exacerbated by policy differences across political boundaries. To address this conundrum, legislation and policies dealing with Pb in electronics are first reviewed. A discussion of the current state of knowledge on alternative solder materials relative to product design, environmental performance, and risk assessment follows. Previous studies are reviewed, and consistent with their results, this analysis finds that there is great uncertainty in the trade‐offs between Pb‐based solders and proposed replacements. Bridging policy and knowledge gaps will require increased international cooperation on materials use, product market coverage, and e‐waste EOL management.     

Bioavailability of Soil-Borne Chemicals: Method Development and Validation

Chemicals present in contaminated soils generally exhibit altered bioavailability compared to other vehicles used in studies of chemical toxicity. Methods used to assess the bioavailability of soil-borne chemicals have generally been modified versions of methods that are widely used in biomedical research. Oral and dermal bioavailability of semivolatile organic chemicals and metals in soil has been assessed by a variety of in vivo and in vitro methods. Due to variations in metabolism and excretion of different chemicals, approaches to measuring bioavailability must be selected with an understanding of disposition of the chemical being studied. Standard methods need to be modified due to constraints associated with doses relevant to environmental concentrations, the need to reflect weathering behavior in soils over time, and the need to generate data applicable to human health risk assessments. Estimates of relative bioavailability for chemicals in soil can be used directly to modify exposure estimates. Application of bioavailability data in a site-specific risk assessment requires regulatory acceptance of the data. Acceptance of the data will generally be dependent on either the use of a validated test method or a careful scientific review of the test method employed. A process for validating newly developed alternative toxicity methods for routine use developed by the Interagency Coordinating Committee on the Validation of Alternative Methods provides relevant guidance for assessing in vitro methods, but method validation should not be the only litmus test for inclusion of bioavailability data in risk assessments.     

The potential role of life cycle assessment in regulation of chemicals in the European union

Scope and Background  This paper presents the preliminary results from an ongoing feasibility study, investigating potential application of elements from the life cycle assessment (LCA) framework in European chemicals’ policy. Many policy areas affect manufacturing, marketing and use of chemicals. This article focuses on the general chemical legislation, especially issues related to regulatory risk assessment and subsequent decisions on risk reduction measures. Method  Current and upcoming chemical regulation has been reviewed and empirical knowledge has been gained from an ongoing case study and from dialogues with various stakeholders. Results and Discussion  LCAs are comparative and more holistic in view as compared to chemical risk assessments for regulatory purposes¹. LCAs may therefore potentially improve the basis for decisions between alternatives in cases where a risk assessment calls for risk reduction. In this process, LCA results might feed into a socio-economic analysis having similar objectives, but some methodological aspects related to system boundaries need to be sorted out. Life cycle impact assessment (LCIA) of toxic effects has traditionally been inspired by the more regulatory-orientated risk assessment approaches. However, the increasing need for regulatory priority setting and comparative/ cumulative assessments might in the future convey LCIA principles into the regulatory framework. The same underlying databases on inherent properties of chemicals are already applied in both types of assessment. Similarly, data on the use and exposure of chemicals are needed within both risk assessments and LCA, and the methodologies might therefore benefit from a joint ‘inventory’ database. Outlook  The final outcome of the feasibility study will be an implementation plan suggesting incorporation of core findings in future chemical regulation and related policy areas.     

An historical overview of the activities in the field of exposure and risk assessment of non-ionizing radiation in Bulgaria

Abstract

The exposure and risk evaluation process in Bulgaria concerning non-ionizing radiation health and safety started in the early 1970s. Then, the first research laboratory “Electromagnetic fields in the working environment” was founded in the framework of the Centre of Hygiene, belonging to the Medical Academy, Sofia. The main activities were connected with developing legislation, new equipment for measurement of electromagnetic fields, new methods for measurement and exposure assessment, in vivo and human studies for developing methods, studying the effect of non-ionizing radiation on human body, developing exposure limits. Most of the occupations as metal industry, plastic welding, energetics, physiotherapy, broadcasting, telephone stations, computer industry, etc., have been covered by epidemiological investigations and risk evaluation. In 1986, the ANSI standard for safe use of lasers has been implemented as national legislation that gave the start for studies in the field of risk assessment concerning the use of lasers in industry and medicine. The environmental exposure studies started in 1991 following the very fast implementation of the telecommunication technologies. Now, funds for research are very insignificant, and studies in the field of risk assessment are very few. Nevertheless, Bulgaria has been an active member of the WHO International EMF Project, since 1997, and that gives good opportunity for collaboration with other Member states, and for implementation of new approach in the EMF policy for workers and people’s protection against non-ionizing radiation exposure.     

Animal models to test respiratory allergy of low molecular weight chemicals: a guidance

At present, there are no widely applied or fully validated test methods to identify respiratory LMW allergens, i.e. compounds that are considered capable of inducing allergic asthma. Most tests have been investigated using strong respiratory allergens. Moreover, they are meant to detect the potential of a chemical to induce respiratory sensitisation at relatively high doses. Consequently, the sensitivity of the tests is not well-known, and they do not provide information on low doses such as generally found in occupational situations, and on threshold levels to be used in risk assessment. In addition, the various test methods use different application routes, i.e. intradermal, topical or inhalation exposure, and different parameters. Therefore standardised and validated dose-response test methods are urgently required in order to be able to identify respiratory allergens and to recommend safe exposure levels for consumers and workers. In the present paper, methods or testing strategies are described to detect respiratory sensitisation and/or allergy. Overall, assays that utilize only an induction phase may serve as indicators of respiratory sensitisation potential whereas assays that use both an induction and an elicitation or challenge phase may provide information on potency and presence of thresholds. The dermal route as sensitisation route has the advantage of the respiratory tract not being exposed to the allergen prior to challenge which facilitates the distinction between irritant and allergic effects.     

Protein biomarkers for in vitro testing of embryotoxicity

There are new challenges for hazard and risk assessment in the chemical industry with regard to REACH legislation in Europe and related activities in the U.S. and Japan, which require the development of novel in vitro models for the molecular characterization of drug- or chemical-related effects replacing conventional animal testing. In the frame of a European FP6 project on reproductive toxicology ( www.reprotect.eu ), we prepared protein samples from mouse embryonic stem cells differentiated into contracting cardiomyocytes according to the validated embryonic stem cell test (EST) protocol, which had been exposed to toxic substances selected by an expert committee from different in vivo categories of embryotoxicity. Lysates were used to carry out the following investigations: (i) identify optimal dose range conditions in the EST that are suitable for (ii) performing a differential quantitative proteomic study of underlying molecular pathways, (iii) define classes of substances with similar proteomic response patterns, (iv) relate these classes to the traditional in vivo categories of embryotoxicity with (v) the final goal to identify novel surrogate protein biomarker candidates for embryo toxicity. We found two distinct classes of toxic substances (Dinoseb, Ochratoxin-A, and Nitrofen vs β-aminoproprionitril, Metoclopramide, Doxylamine succinate, and d-penicillamine) with clear pathway-related differences in their proteomic patterns. Most notably, different responses to cluster 1 and cluster 2 substances were observed for Heat shock protein β-1, Ras-GTPase-activating protein SH3-domain binding protein, Ran binding protein 5, and Calreticulin, Dihydropyrimidinase-like 2 (Ulip2 protein). On the other hand, Heat shock protein 8 and Fscn1 protein were down-regulated by all compounds from both clusters.     

Modeling of purification operations in biotechnology: enabling process development, optimization, and scale-up

Process modeling involves the use of a set of mathematical equations to represent key physical phenomena involved in the process. An appropriately validated model can be used to predict process behavior with limited experimental data, identify critical ranges for process variables, and guide further process development. Although process modeling is extensively used in the chemical process industries, it has not been widely used in purification unit operations in biotechnology. Recent FDA guidelines encourage the use of process modeling during process development, along with multivariate statistical methods, detailed risk assessment, and other quantifiers of uncertainty. This paper will review recent advances in the modeling of key downstream unit operations: chromatography, filtration, and centrifugation. The focus will be on the application of modeling for industrial applications. Relevant papers presented at a session on this topic at the recent American Chemical Society National Meeting in San Francisco will also be reviewed.     

生态风险评价研究进展

20多年来,生态风险评价研究经历了从环境风险到生态风险到区域生态风险评价的发展历程,风险源由单一风险源扩展到多风险源,风险受体由单一受体发展到多受体,评价范围由局地扩展到区域景观水平.区域生态风险评价就是大尺度上研究复杂环境背景下包含多风险源、多风险受体的综合风险研究.目前,区域生态风险评价的理论框架已经搭建起来,统计方法多采用相对评价法.区域生态风险评价未来的发展方向为继续加强实验和野外调查,进一步减小不确定性,逐步解决尺度推移问题.区域生态风险评价必须与经济、社会、文化相结合,才能充分发挥它在管理决策中的作用.     

Applying a weed risk assessment approach to GM crops

Current approaches to environmental risk assessment of genetically modified (GM) plants are modelled on chemical risk assessment methods, which have a strong focus on toxicity. There are additional types of harms posed by plants that have been extensively studied by weed scientists and incorporated into weed risk assessment methods. Weed risk assessment uses robust, validated methods that are widely applied to regulatory decision-making about potentially problematic plants. They are designed to encompass a broad variety of plant forms and traits in different environments, and can provide reliable conclusions even with limited data. The knowledge and experience that underpin weed risk assessment can be harnessed for environmental risk assessment of GM plants. A case study illustrates the application of the Australian post-border weed risk assessment approach to a representative GM plant. This approach is a valuable tool to identify potential risks from GM plants.     

An Approach for Incorporating Information on Chemical Availability in Soils into Risk Assessment and Risk-Based Decision Making,Prepared by: The New England Environmentally Acceptable Endpoints Workgroup

A regional workgroup comprised of individuals from regulatory agencies, uni versities, and consulting companies was formed to develop an approach for incor porating information on chemical availability in soils into risk assessment and risk based decision making. The approach consists of the following decision framework for including information on chemical availability: (1) Determine the usefulness of incorporating information on bioavailability; (2) Identify information needs from a conceptual model of exposure for the site and from exposure pathways judged critical to the assessment; (3) Identify soil factors that affect bioavailability; (4) Determine the type or form of information (measures and/or models) that can be used within the risk assessment and risk management process; (5) Select methods (measures and/or models) based on the “weight of evidence” or strength of the bioavailability information they will provide and how that information will be used for risk assessment and risk based decision making; (6) Incorporate information into the risk assessment and risk based decision making. These fac tors can be integrated into existing risk based approaches for site management such as Superfund, state approaches, and the ASTM Risk Based Corrective Action Process (RBCA). Consistent with risk assessment guidance, an assessment of chemical availability in soils must consider current as well as reasonably foresee able conditions. The approach recognizes that information on chemical availabil ity is contextual and depends on the receptor and pathway. Further, the value of information depends on how well it is accepted and/or validated for use in regulatory decision making. The workgroup identified four principles for select ing methods (measures and/or models) for obtaining information on chemical availability and for evaluating information on chemical availability for use in risk assessments: (1) soil chemical relevance, (2) pathway relevance, (3) receptor relevance, and (4) acceptance of the method.     

Chemical Mixtures: An Unsolvable Riddle?

It is difficult to overstate the complexity of assessing risks from chemical mixtures. For every valid reason to assess risks from mixtures, there appears an equally valid question as to whether it is possible to do so in a scientifically rigorous and relevant manner. Because so few data exist for mixtures, current mixture assessment methods must rely on untested assumptions and simplifications. That the accuracy of risk estimates improve with the number of chemicals assessed together as mixtures is a valid assumption only if assessment methods for mixtures are better than those based on individual chemicals. On the other hand, arbitrarily truncating a mixture assessment to make it manageable may lead to irrelevant risk estimates. Ideally, mixture assessments should be as broad as necessary to improve accuracy and reduce uncertainty over assessments that only use toxicity data for single chemicals. Further broadening the scope may be ill advised because of the tendency to increase rather than decrease uncertainty. Risk assessment methods that seek to be comprehensive at the expense of increased uncertainty can hardly be viewed as improvements. It would be prudent to verify that uncertainty can be reduced before burdening the risk assessment process with more complexity.     

Prospects for applying genotypic selection of somatic oncomutation to chemical risk assessment.

Genotypic selection methods detect rare sequence changes in populations of DNA molecules. These methods have been used to investigate the chemical induction of mutation and for the detection and diagnosis of cancer. The possible use of genotypic selection for improving current risk assessment practices is based on the premise that the frequency of somatic mutation is of critical importance in understanding and modeling carcinogenesis. If genotypic selection can measure the induction of specific mutations that disrupt normal cell/tissue homeostasis, then it could provide key mechanistic information for cancer risk assessment. For example, genotypic selection data might support a particular low-dose extrapolation method or characterize the relationship between rodent and human cancer risk. Strategies for evaluating the use of genotypic selection in cancer risk assessment include the concept of developing a battery of targets that detect a range of agent-specific effects. Ideal targets to examine by genotypic selection are the oncogene and tumor suppressor gene mutations frequently detected in human tumors because these are thought to represent tumor-initiating events. The most commonly occurring basepair (bp) substitutions within the ras and p53 genes are identified. Also, the battery of genotypic selection methods is defined in terms of the most important mutational specificities to include. In theory, the major basepair substitution mutations induced by 29 of 31 chemical carcinogens could be detected by analyzing three different mutations: G:C-->T:A, G:C-->A:T, and A:T-->T:A. Genotypic selection will have the greatest impact on risk assessment if measurement of spontaneous mutation is possible. Data from phenotypic selection assays suggest this corresponds to detection of mutant fractions of approximately 10(-7), and this would necessitate examining DNA samples containing >10(7) target molecules. Despite its apparent potential, considerable development and validation is needed before genotypic selection data can be applied to cancer risk assessment.